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The article follows men age 50-59 between 1999 and 2009 
that were newly diagnosed with clinically localized prostate 
cancer. They were then separated randomly into 3 different 
groups including active surveillance, radiotherapy, and 
radical prostatectomy. The purpose was to gauge the 
effectiveness of treatments in terms of premature death. The 
importance of this study was to evaluate for an incredibly 
pressing concern of prostate cancer throughout not only the 
United States, but worldwide. There are uncertainties when it 
comes to the way prostate cancer is diagnosed and its 
correlation to treatment outcomes. This study (a two-part 
study initially published in 2014) found low cancer specific 
mortality regardless of treatment.2 The study referred to its 
initial randomized trial which focused more on methodology 
of diagnosis as well as other literature with randomized trials 
comparing prostatectomy with active surveillance or 
radiotherapy. These ranged from randomized controlled 
studies to patient reported outcomes. The active monitoring 
group differs from previous studies incorporating “watchful 
waiting” such as the Scandinavian Prostate Cancer Group 
Study Number 4 and the U.S. Prostate Cancer Intervention 
versus Observation Trial (PIVOT).3,4,5 In the current study 
patients were assessed for changes in PSA levels and as a 
result clinical management could be modified whereas in the 
2 latter studies mentioned no intervention was provided.3,4,5
Despite the differences among the trials PIVOT concluded 
that there was not a significant difference in cancer-specific 
mortality rates between watchful waiting and radical 
prostatectomy. However, amongst the Scandinavian trials it 
was concluded that radical prostatectomy helped to reduce 
cancer-specific mortality, but did not have a difference 
between overall survival.3,6 Adding in the perspective of 
prostatectomy versus radiotherapy, a meta-analysis 
completed found increased overall risk of mortality, both non 
cancer-specific and cancer-specific.7 Per a retrospective 
study there was an insignificant difference found amongst 
prostatectomy and radiotherapy.8
This study was a prospective trial that compared active 
monitoring, radical prostatectomy, and external-beam 
radiotherapy for the treatment of localized prostate cancer. A 
total of 82,429 men 50 to 69 years of age received a PSA 
test between 1999 and 2009. Of that 2664 received the 
diagnosis of clinically localized prostate cancer, and 1643 
agreed to undergo randomization. After randomization 545 
men were active monitoring, 545 underwent radiotherapy, 
and 553 men underwent surgery. The goal of randomization 
was to ensure the groups were made to be as similar in 
demographics as possible with respect to age, Gleason 
score, mean baseline from the first biopsy and PSA test. 
Prostate-cancer mortality at a median of 10-year follow-up 
was the primary outcome. The secondary outcome included 
the rates of disease progression, metastases, and all deaths. 
A total of 14 patients were lost to follow up for secondary 
outcomes, but data on deaths were captured for all 
participants. Sensitivity analyses excluded men that were 
recruited during the feasibility phase or that included deaths 
that were judged to be possibly due to prostate cancer. Men 
were also excluded based on PSA test results from the initial 
randomized control trial. 
Figure 1. Randomization, Treatment, and Follow-up.A 
total of 88% of the men assigned to active monitoring, 71% of 
the men assigned to surgery, and 74% of men assigned to 
radiotherapy received the assigned treatment within 9 
months after randomization. A total of 14 patients were lost to 
follow-up for secondary outcomes, but data on deaths were 
captured for all participants.
Table 2. Deaths from Prostate Cancer, According to 
Subgroup.
The results found that of the 1643 men included, 14 were lost 
to follow up due to outcomes during the follow up period, but 
were still included in the study. They found secondary issues 
within the study where 291 of the active monitoring group 
ended up receiving some sort of radical treatment, which 
included surgery and/or radiotherapy. Of the prostatectomy 
group, 6 had to receive some sort of radiotherapy 1-year post 
surgery. Of the radiotherapy group, 3 had to undergo savage 
prostatectomy, and 15 received additional treatment. They 
determined that 7-8 of the deaths in the active surveillance 
group were prostate cancer specific, 3-5 in the surgery 
group, and 4 in the radiotherapy group. Survival specific to 
prostate cancer was determined to be around 98.8% in all 
groups with an insignificant difference between the groups. 
204 out of the total men were found to have disease 
progression including metastasis (46 in the surgery, 112 in 
the active surveillance, and 46 in the radiotherapy group). 
There were minimal complications reported post treatment 
although there were 3 deaths determined to be unrelated to 
prostate cancer in the radiotherapy group. Numbers needed 
to treat were determined to be 27 men for prostatectomy for 
1 avoiding metastatic disease and 33 with radiotherapy. If 
combined the number lowers to 9 men. The author 
concluded that amongst all three treatment groups there was 
no significant difference in prostate-cancer related deaths 
over a 10-year span post intervention. However, it found that 
prostatectomy and radiotherapy were associated with lower 
incidences of progressing disease as opposed to the active 
monitoring group. The long-term effects of intervention still 
need to be evaluated to form a more educated and evidence-
based decision on treatment. One factor not incorporated or 
considered in the study was quality of life for which the 
author appears to want to follow up on in future studies. The 
study was limited in not considering quality of life or the 
specific outcomes post-surgical or radiotherapy. With the 
smaller sample size and the sample being solely out of the 
UK certain factors such as if there are any differences in the 
prostate cancer seen in the UK versus anywhere else in the 
world was not addressed. The study and the previous 
randomized trial can help to try and establish the benefit of 
PSA testing in diagnosis of prostate cancer regarding overall 
outcomes. 
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Figure 2. Kaplan–Meier Estimates of Prostate-Cancer–Specific 
Survival and Freedom from Disease Progression, According to 
Treatment Group Panel A shows the rate of prostate-cancer–
specific survival. Prostate-cancer–specific deaths were those 
that were definitely or probably due to prostate cancer or its 
treatment, as determined by an independent cause-of-death 
evaluation committee whose members were unaware of the 
treatment assignments. Panel B shows the rate of freedom from 
disease progression. Clinical progression of prostate cancer 
included metastasis and death due to prostate cancer or its 
treatment.
